/
ONCO
$0.95-$0.02 (-2.27%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$3.6M
4M shares
52-week range
$0.88 – $270.00
0% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
121.29%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-32299.05
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $58.5K | $2.5M | $815.4K |
| Cost of revenue | $573 | $3.1K | $4.9K | $6.8K | $1.2M | $1.5M | $182.5K |
| Gross profit | −$573 | −$3.1K | −$4.9K | −$6.8K | −$1.1M | $1.1M | $632.9K |
| Gross margin | — | — | — | — | -1927.9% | 41.8% | 77.6% |
| R&D | $60.2K | $524.9K | $1.3M | $4.1M | $1.9M | $154.4K | −$66.1K |
| Operating income | −$880.2K | −$1.6M | −$3.4M | −$13.5M | −$36.0M | −$56.5M | −$6.3M |
| EBITDA | −$821.3K | −$1.6M | −$3.4M | −$13.4M | −$36.7M | −$57.6M | −$13.3M |
| Net income | −$821.9K | −$1.6M | −$3.4M | −$13.4M | −$37.4M | −$58.7M | −$14.0M |
| Net margin | — | — | — | — | -63986.5% | -2325.2% | -1721.0% |
| EPS (diluted) | -0.02 | -0.04 | -0.09 | -0.31 | -25.03 | -520.93 | -4.73 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $881218 | $-200600.00 | $-200600.00–$-200600.00 | 1 |
| 2027 | $952384 | $-214200.00 | $-214200.00–$-214200.00 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.39
Price
$0.95
Implied upside
+45%
Peer comparison
Onconetix, Inc. Common Stock
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
www.onconetix.com- Employees
- 2
- IPO / List date
- Feb 18, 2022
- HQ
- CINCINNATI, OH
Held by traders on TradeandTell
No one on the platform currently holds ONCO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ONCO as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-05-21 | 1-for-10reverse |
| 2026-03-25 | 1-for-5reverse |
| 2025-06-13 | 1-for-85reverse |
| 2024-09-24 | 1-for-40reverse |
| 2016-09-28 | 1-for-1500reverse |
Recent trades on TradeandTell
No one on the platform has traded ONCO yet.
